A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Steroid Biochemistry and Molecular Biology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jsbmb.2016.04.007PMID 27106747
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.

  2014cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Bicalutamide 150mg

  2012cited by this paper
• Androgen receptor signaling in prostate cancer development and progression

  2011cited by this paper
• Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness

  2011cited by this paper
• Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

  2011cited by this paper
• Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin.

  2010cited by this paper
• NCCN clinical practice guidelines in oncology: prostate cancer.

  2010cited by this paper
• Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

  2009cited by this paper
• Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands

  2009cited by this paper
• Androgen Action in Prostate Cancer

  2009cited by this paper
• Cognitive effects of hormone therapy in men with prostate cancer

  2008cited by this paper
• Prostate cancer. Clinical practice guidelines in oncology.

  2007cited by this paper
• A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats.

  2007cited by this paper
• Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

  2006cited by this paper
• Side‐effects of treatments for locally advanced prostate cancer

  2006cited by this paper
• What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?

  2006cited by this paper
• 78 Use of a rabbit model to investigate the feasibility of using an innervated neosphincter transplant for the treatment of stress urinary incontinence.

  2006cited by this paper
• Molecular regulation of androgen action in prostate cancer

  2006cited by this paper
• Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.

  2005cited by this paper
• Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours

  2005cited by this paper
• Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation

  2005cited by this paper
• Androgen receptor in prostate cancer.

  2004cited by this paper
• Role of stromal-epithelial interactions in hormonal responses.

  2004cited by this paper
• Complications of androgen-deprivation therapy for prostate cancer.

  2004cited by this paper
• The biological role of estrogen receptors α and β in cancer

  2004cited by this paper
• The biological role of estrogen receptors alpha and beta in cancer.

  2004cited by this paper
• The physical burden of prostate cancer.

  2003cited by this paper
• Regulation of testicular function in men: implications for male hormonal contraceptive development.

  2003cited by this paper
• Complications of androgen deprivation therapy for prostate cancer

  2003cited by this paper
• Critical Review and Evaluation of the Uterotrophic Bioassay for the Identification of Possible Estrogen Agonists and Antagonists: In Support of the Validation of the OECD Uterotrophic Protocols for the Laboratory Rodent

  2002cited by this paper
• Molecular biology of the androgen receptor.

  2002cited by this paper
• Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

  2001cited by this paper
• Testosterone dose-response relationships in healthy young men.

  2001cited by this paper
• The Dunning model

  2000cited by this paper
• Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability.

  1995cited by this paper
• Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

  1994cited by this paper
• Effects of antiandrogens and ethane dimethane sulphonate (EDS) on gene expression, free subunits, bioactivity and secretion of pituitary gonadotrophins in male rats.

  1993cited by this paper
• "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.

  1989cited by this paper
• Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers

  1987cited by this paper
• Effects of gonadectomy and exogenous gonadal steroids on sex differences in open field behaviour of adult rats.

  1981cited by this paper
• Regulation of prolactin binding sites in the seminal vesicle, prostate gland, testis and liver of intact and castrated adult rats: effect of administration of testosterone, 2-bromo-alpha-ergocryptine and fluphenazine.

  1979cited by this paper
• Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.

  1978cited by this paper
• An effect of castration and testosterone replacement on a circadian pacemaker in mice (Mus musculus).

  1975cited by this paper
• Secretory function of the prostate, seminal vesicle and other male accessory organs of reproduction.

  1974cited by this paper
• PROSTATE CANCER IN THE RAT.

  1963cited by this paper
• PROSTATE CANCER IN THE RAT.

  1963cited by this paper

• Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy

  2025cites this paper
• Ligandrol lowers endurance and negatively affects lipid and hormonal profile of male rats

  2025cites this paper
• Unveiling the Potential of S4 on Non-small Cell Lung Cancer Cells: Impact on Proliferation, Apoptosis, Senescence, and Metabolome Profile.

  2025cites this paper
• Reported adverse effects of SARMs in animals and humans: A review

  2024cites this paper
• Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management

  2023cites this paper
• Safety of androgen therapy in men with prostate cancer.

  2022cites this paper
• Non-targeted detection of designer androgens: Underestimated role of in vitro bioassays.

  2021cites this paper
• Front Pages PAUL GODBOUT Knowing and Understanding how to Manage One’s Physical Activity Practice: Contribution of Language, Thinking and Intelligence to Physical Literacy BRAD STRAND An Analysis of Coaches’ Perceptions of Inappropriate Coaching Behaviors

  2021cites this paper
• Selective Androgen Receptor Modulators (SARMs) in Sports: A Review

  2021cites this paper
• Combined Effects of Exercise and Phytoanabolic Extracts in Castrated Male and Female Mice

  2021cites this paper
• Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers

  2021cites this paper
• A selective androgen receptor modulator SARM‐2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys

  2020cites this paper
• Selective androgen receptor modulators: the future of androgen therapy?

  2020cites this paper
• Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials

  2020cites this paper
• Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science

  2020cites this paper
• Discovery and Development of Azasteroids as Anticancer Agents.

  2019cites this paper
• Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

  2019cites this paper
• Androgen receptor co-regulation in prostate cancer

  2019cites this paper
• Deep graph embedding for prioritizing synergistic anticancer drug combinations

  2019cites this paper
• DrugComb: an integrative cancer drug combination data portal

  2019cites this paper
• DrugComb - an integrative cancer drug combination data portal

  2019cites this paper
• Nuclear receptors: recent drug discovery for cancer therapies.

  2019cites this paper
• A magic drug target: Androgen receptor

  2019cites this paper
• Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells.

  2018cites this paper
• Androgen and estrogen actions on male physical activity: a story beyond muscle.

  2018cites this paper
• Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

  2018cites this paper
• Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays

  2018influential citation
• Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.

  2017cites this paper
• BA321, a novel carborane analog that binds to androgen and estrogen receptors, acts as a new selective androgen receptor modulator of bone in male mice.

  2016cites this paper